Navigation Links
Early Switch to an Aromatase Inhibitor Increases Survival

For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates//, according to a new study. The study reveals that the clear survival benefit was also achieved without an increased risk of death from other causes – a significant risk associated with tamoxifen.

Hormone modulating therapies have made a significant impact on the survival rates of women with estrogen-sensitive breast cancer over the last two decades. The drugs are used as adjuvant to primary surgical treatment for a period of five years.

Tamoxifen was the first estrogen modulator shown to increase survival and reduce the risk of breast cancer recurrence. However, tamoxifen is associated with increased risk of death from other causes, such as strokes and endometrial cancer. Despite this risk, tamoxifen and another drug in this class, raloxifene, remain an extensively used and popular treatment.

Aromatase inhibitors, such as aminoglutethimide and anastrozole, work in a different way to lower estrogen levels. Recent evidence shows aromatase inhibitors used alone or in follow-up after two years of tamoxifen therapy demonstrates clear and, in some cases, improved reduction of recurrence risk. However, there is conflicting evidence about mortality benefits.

Led by Professor Francesco Boccardo, M.D. of the National Cancer Research Institute and the University of Genoa in Italy, researchers pooled data from two studies (828 women) comparing five year treatment with tamoxifen alone (415 women) or tamoxifen for two to three years followed by an aromatase inhibitor for the remaining treatment period (413 women).

Dr. Boccardo and his colleagues found that compared to treatment with tamoxifen alone, all cause mortality risk and breast cancer-related mortality risk both fell significantly for women switching to an aromatase inhibitor. In addition, there was no increased risk of de ath from other causes in women who were prescribed the aromatase inhibitor.

"This pooled analysis provides solid evidence that switching to an aromatase inhibitor following a few years of tamoxifen treatment, implies a mortality benefit over continued tamoxifen and that the benefit on breast cancer-related mortality is mainly due to the effect of switching," conclude the authors.

Source-Eurekalert
'"/>




Related medicine news :

1. Early detection of prostate cancer
2. Early detection of heart attack
3. Early puberty linked to nutrition
4. Early Clue to Down Syndrome
5. Early delivery can prevent cancer
6. Early puberty more resistance
7. Early menopause- The cause
8. Early menopause- The cause
9. Early Warning System For Breast Cancer
10. Early therapy aids eyesight
11. Early detection of colorectal cancer may be hindered by coloured toilet disinfectants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... 29, 2016 , ... Reltok Nasal Products proudly announces that Boston Medical Products, ... nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product ... a newly patented safety device secured by nasal surgeons onto the floor of the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... media enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, ... as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... and hospice software, outsourced billing and coding services, and Deyta Analytics, recently announced ... hospices providing the highest level of quality as measured from the caregiver’s point ...
(Date:4/29/2016)... ... April 29, 2016 , ... Pro3rd Grunge is a ... Film Studios’ lower thirds to introduce people, characters, and locations without having to set ... lines, accents, textures and many more design components. Simply select a preset and drag ...
(Date:4/28/2016)... ... 2016 , ... Monthly subscription boxes are all the rage, and "My Subscription ... the ZEN BOX , the aromatherapy subscription box. , ZEN BOX delivers three new ... frankincense) and one Zen Blend (like immune boost, sublime sleep or de-stress blends) ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 Dr. Vivek Ahuja , ... Ste phen Schmidt ... provider of cloud-based software solutions for life sciences, today announced key ... a wealth of insight to a growing business.  This will bolster ... George Phillips joined ArisGlobal in the position of Vice ...
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... TURIN, Italy , April 27, 2016 ... MR-guided linear accelerator (MR-linac) platform will be the focal ... annual meeting of the European Society for Radiotherapy & ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and ... a physician to clearly see the patient,s anatomy in ...
Breaking Medicine Technology: